Musculoskeletal pain Market: Rapid Increment Driven by Innovation by 2034- DelveInsight

The Musculoskeletal pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Musculoskeletal pain pipeline products will significantly revolutionize the Musculoskeletal pain market dynamics.

DelveInsight's "Musculoskeletal pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Musculoskeletal pain, historical and forecasted epidemiology as well as the Musculoskeletal pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Musculoskeletal pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 20120 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Musculoskeletal pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Musculoskeletal pain Market Forecast
https://www.delveinsight.com/sample-request/musculoskeletal-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Musculoskeletal pain Market Report:
• The Musculoskeletal pain market size was valued at USD 3,647.2 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In January 2026, NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), a South Korea-based medical device innovator, announced that Health Canada has approved Nexsphere-FTM, its newly developed fast-resorbable microsphere for musculoskeletal pain embolization. Nexsphere-FTM is engineered to temporarily block abnormal blood vessels linked to osteoarthritis-associated pain. By using resorbable microspheres, the procedure triggers targeted necrosis of pain-transmitting nerve cells within approximately 2 to 8 hours post-treatment, leading to effective pain reduction.
• In November 2025, Accord BioPharma, Inc., the specialty arm of Intas Pharmaceuticals, Ltd. dedicated to oncology, immunology, and critical care therapeutics, announced that the U.S. Food and Drug Administration (FDA) has approved OSVYRTI® (denosumab-desu), a biosimilar to Prolia® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to Xgeva® (denosumab). These approvals represent Accord BioPharma's fourth and fifth biosimilar authorizations, underscoring the company's expanding presence in the U.S. market. With respect to musculoskeletal pain, denosumab products have been associated with severe and, in some cases, disabling bone, joint, and/or muscle pain; discontinuation of OSVYRTI should be considered if significant symptoms occur.
• The total 7MM diagnosed prevalent cases of musculoskeletal pain in 2020 were 145,426,730 cases
• Among the 7MM countries the highest prevalence of Musculoskeletal pain were observed in the United States
• In 2020, there were 76,331,935 diagnosed prevalent cases of musculoskeletal pain in the United States
• Key Musculoskeletal pain Companies: Mesoblast, Eli Lilly and Company, Regenron, Teva, Taiwan Liposome, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others
• Key Musculoskeletal pain Therapies: Rexlemestrocel-L (MPC-06-ID), LY3556050 (Mazisotine), MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others
• The musculoskeletal pain epidemiology based on gender analyzed that in the United States, musculoskeletal pain is more prevalent in females than in males

Musculoskeletal pain Overview
Musculoskeletal pain refers to pain that affects the muscles, bones, ligaments, tendons, and nerves. It can be acute (short-term) or chronic (long-term) and can affect any part of the musculoskeletal system, including the neck, back, joints, and limbs.

Get a Free sample for the Musculoskeletal pain Market Report:
https://www.delveinsight.com/report-store/musculoskeletal-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Musculoskeletal pain Market
The dynamics of the Musculoskeletal pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2020-2034.

Musculoskeletal pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Musculoskeletal pain epidemiology trends @ Musculoskeletal pain Epidemiological Insights
https://www.delveinsight.com/sample-request/musculoskeletal-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Musculoskeletal pain Epidemiology Segmentation:
The Musculoskeletal pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Musculoskeletal pain
• Prevalent Cases of Musculoskeletal pain by severity
• Gender-specific Prevalence of Musculoskeletal pain
• Diagnosed Cases of Episodic and Chronic Musculoskeletal pain

Musculoskeletal pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Musculoskeletal pain market or expected to get launched during the study period. The analysis covers Musculoskeletal pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Musculoskeletal pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Musculoskeletal pain Therapies and Key Companies
• Rexlemestrocel-L (MPC-06-ID): Mesoblast
• LY3556050 (Mazisotine): Eli Lilly and Company
• MPC-06-ID: Mesoblast
• Fasinumab: Regenron/Teva
• TLC599: Taiwan Liposome
• LY3016859: Eli Lilly
• AXS-14: Axsome Therapeutics
• Lorecivivint: Biosplice Therapeutics
• CNTX-4975: Centrexion Therapeutics
• X0002: Techfields Pharma

To know more about Musculoskeletal pain treatment, visit @ Musculoskeletal pain Medications
https://www.delveinsight.com/sample-request/musculoskeletal-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Musculoskeletal pain Market Drivers
• Rising prevalence of musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, and chronic low back pain
• Aging global population, increasing susceptibility to joint degeneration and chronic pain conditions
• Growing incidence of sports injuries, occupational strain, and lifestyle-related conditions
• Increasing awareness and diagnosis of chronic pain conditions
• Advancements in pain management therapies, including biologics, regenerative medicine, and non-opioid analgesics
• Expanding demand for minimally invasive treatments and personalized pain management approaches
• Improved access to healthcare services in emerging markets

Musculoskeletal pain Market Barriers
• Safety concerns and adverse effects associated with long-term use of pain medications, especially opioids and NSAIDs
• High cost of advanced therapies and limited reimbursement in several regions
• Stringent regulatory requirements and lengthy approval timelines for novel pain treatments
• Variability in patient response and limited long-term efficacy of existing therapies
• Limited availability of specialized pain management centers in low- and middle-income countries
• Challenges in differentiating new therapies in a crowded and competitive market

Scope of the Musculoskeletal pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Musculoskeletal pain Companies: Mesoblast, Eli Lilly and Company, Regenron, Teva, Taiwan Liposome, Axsome Therapeutics, Biosplice Therapeutics, Centrexion Therapeutics, Techfields Pharma, and others
• Key Musculoskeletal pain Therapies: Rexlemestrocel-L (MPC-06-ID), LY3556050 (Mazisotine), MPC-06-ID, Fasinumab, TLC599, Eli Lilly, AXS-14, Lorecivivint, CNTX-4975, X0002, and others
• Musculoskeletal pain Therapeutic Assessment: Musculoskeletal pain current marketed and Musculoskeletal pain emerging therapies
• Musculoskeletal pain Market Dynamics: Musculoskeletal pain market drivers and Musculoskeletal pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Musculoskeletal pain Unmet Needs, KOL's views, Analyst's views, Musculoskeletal pain Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.